Viking Therapeutics VKTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$472.34M-31.3% | -$359.64M-51.5% | -$237.39M-38.4% | -$171.55M-33.8% | -$128.24M-16.6% | ||
| $39.81M-2.5% | $40.82M+7.7% | $37.9M-4.2% | $39.54M+19.5% | $33.08M+11.3% | ||
| -$340.33M-22.1% | -$278.69M-24.1% | -$224.58M-47.2% | -$152.54M-13.8% | -$133.99M-52.6% | ||
| $332.33M-2.7% | $341.39M— | —— | —— | —— | ||
| $88.17M+15.3% | $76.44M+3,172% | $2.34M-46.6% | $4.38M-35.4% | $6.78M-98.9% | ||
| $84.22M-41.2% | $143.19M+164% | $54.17M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viking Therapeutics's cash flow data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.